On 25 July 2024 the European Medicines Agency (EMA) rejected a licence for lecanemab to treat Alzheimer’s disease. The EMA said the benefits did not counterbalance the risk of serious side effects, especially bleeding and swelling in the brain. The MHRA in the UK is still considering whether to grant a licence, and a decision is…
Category: Alzheimer’s Disease
Kisunla (donanemab) gains full FDA approval
Lilly’s Alzheimer’s drug is a challenger for Biogen and Eisai’s Leqembi July 2, 2024: Eli Lilly’s anti-amyloid therapy donanemab for Alzheimer’s disease was rejected for accelerated approval last year, but the FDA has now given it full approval. The FDA has cleared donanemab-abzt, branded as Kisunla, to treat adults with early symptomatic Alzheimer’s disease, including people…
How can scientists model the human brain?
bit.bio launches ioAstrocytes For the first time, scientists can now leverage the reproducibility of ioCells to study how the four major CNS cell types interact and contribute to neurological diseases. This enables more precise research and opens new doors for developing effective treatments. bit.bio, the company coding human cells for novel cures and a pioneer…
Blood tests for diagnosing dementia a step closer for UK
Blood tests for diagnosing dementia are a step closer for UK
Biogen drops Alzheimer’s drug Aduhelm
31 January 2024; Biogen has announced that it will discontinue the development and commercialisation of ADUHELM® (aducanumab-avwa) 100 mg/mL injection for intravenous use and will terminate the ENVISION clinical study. This decision is not related to any safety or efficacy concerns. A large portion of the resources released resulting from termination of the ADUHELM programme will…
New twice weekly Alzheimer’s disease patch
Alzheimer’s disease treatment can help reduce symptoms and lessen the care burden for patients and their caregivers September 2023: Zeyzelf® twice weekly rivastigmine transdermal patch is for the symptomatic treatment of mild to moderately severe Alzheimer’s dementia and it is the first ever patch to be launched in the UK that does not need daily…
Can the scent of essential oils improve memory?
From Medscape, August 8th 2023. Inhaling a pleasant aroma during sleep has been linked to an improvement in memory, small-scale early research suggests. Researchers randomly assigned 43 older adults, aged 60 – 85 years, to receive either nightly exposure to essential oil scents delivered via a diffuser (n = 20; mean [SD] age, 70.1 [6.6]…
FDA approves LEQEMBI™ (lecanemab-irmb)
Traditional approval for the treatment of Alzheimer’s disease in the US July 6, 2023: Eisai Co Ltd and Biogen Inc have announced that the US Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) supporting the traditional approval of LEQEMBI® (lecanemab-irmb) 100 mg/mL injection for intravenous use, making LEQEMBI the first and…
THN391 – First in-human dosing in phase 1 trial in Alzheimer’s disease
Therini Bio Initiates First-In-Human Dosing in Phase 1 Trial of THN391, a Fibrin-Targeting Therapeutic Candidate for Alzheimer’s Disease THN391 binds to the inflammation-driving component of fibrin that is known to activate pathological immune responses in neurodegenerative and ophthalmologic diseases. Based on preclinical studies to date, targeting this region does not impact or diminish fibrin’s critical…
